Top of this page
Skip navigation, go straight to the content

Our Company

Disease Areas

Our Science

UCB Worldwide

 Search

Our Products

Newsroom

Patients

Investors

FOLLOW US ON
© 2007 – 2019 UCB S.A., Belgium. All rights reserved.
Newsroom • Press Releases

Search Press releases


Transparency notifications BlackRock, Inc.24 Jun 2019

Transparency notifications BlackRock, Inc.

Read more
UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients13 Jun 2019

UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for …

Read more
Transparency notifications BlackRock, Inc.12 Jun 2019

Transparency notifications BlackRock, Inc.

Read more
UCB Showcases the Depth of its Immunology Research and Commitment to Patients at EULAR 201906 Jun 2019

UCB Showcases the Depth of its Immunology Research and Commitment …

Read more
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.19 May 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA …

Read more
Transparency notifications BlackRock, Inc.02 May 2019

Transparency notifications BlackRock, Inc.

Read more


Stay up-to-date on the latest news and information from UCB